Woman of the Week: CinCor Pharma's Terry Coelho

From M&Ms to biotech, the chief financial officer's sweet tooth for taking risks is paying off. 

By Taren Grom • July 6, 2022

Pharma companies take a fresh approach to inclusion in new DTC ads

AstraZeneca and Amgen are emphasizing diversity and authenticity in campaigns for lupus and severe asthma therapies.

By Karissa Waddick • July 5, 2022

Explore the Trendline➔

Commercialization, marketing and social media

As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical. 

By PharmaVoice staff

Biotech spotlight: Twist Bioscience aims to remove limits on drug discovery with DNA synthesis platform

As ‘the Amazon of DNA,’ Twist CSO, Aaron Sato, discusses the company’s breakthrough approach to DNA production and its expansion into drug development.

By Kim Ribbink • June 30, 2022

Making moves: Walgreens, Merck, eClinical Solutions and more announce key new hires

The latest personnel changes from around the industry.

By Karissa Waddick • June 29, 2022

The scientist's struggle: Lessons from the journey of mRNA pioneers Katalin Karikó and Drew Weissman

The two Penn Medicine researchers whose work brought the mRNA vaccines into COVID-19 fruition want to see the pharma world embrace early science.

By Michael Gibney • June 29, 2022

From vineyards to antivirals, Gilly Regev brings creative thinking to science

The CEO of SaNOtize is tapping into outside-the-box innovation to develop a nitric oxide-delivery platform to treat and prevent COVID-19.

By Alexandra Pecci • June 27, 2022

A myriad of blows: Who's getting hit the hardest by the economy's troubles

The downturn shows few signs of hurting large pharma, but small biotechs and generics makers could face a credit crunch.

By Kim Ribbink • June 27, 2022

4 tips for landing your next C-suite role in pharma

Even execs get the blues — and when they’re ready for a fresh start, Leslie Loveless, CEO of Slone Partners, says these dos and don’ts could make or break their next job move.

By Meagan Parrish • June 23, 2022

Woman of the Week: Kronos Bio's Barbara Kosacz

Deal-maker, mentor and biotech industry mover and shaker, the COO and general counsel brings her 'smiling tiger' skills to her new role at the emerging company.

By Taren Grom • June 21, 2022

#DIA2022: How the industry's top regulator views the future of healthcare

In the evolution of healthcare, data is the linchpin to making drug development more efficient.

By Michael Gibney • June 21, 2022

Biotech spotlight: Karuna Therapeutics’ mission to rejuvenate the field of neuroscience

An effective treatment for psychiatric disorders such as schizophrenia might require a holistic approach to avoid serious side effects, says CEO Steve Paul.

By Kim Ribbink • June 16, 2022

A patient-funded ALS drug offers hope where few treatments exist

Eledon Pharmaceuticals’ grassroots-backed drug recently entered clinical trials.

By Kelly Bilodeau • June 15, 2022

Woman of the Week: Tango Therapeutics' Dr. Barbara Weber

A pioneer in genetic medicine, Dr. Barbara Weber continues to push the envelope to expand the reach of therapies based on genetic targeting.

By Taren Grom • June 14, 2022

Why biomanufacturing is the next innovation frontier for genomic therapies

While cell and gene therapy research has accelerated quickly, manufacturing in the space hasn’t quite kept up, Danaher’s Chief Science Officer JC Gutiérrez-Ramos says.

By Meagan Parrish • June 13, 2022

First 90 Days: Editas Medicine’s Gilmore O’Neill

The first-time CEO is flexing new muscles as he steers the gene editing company through clinical trials and beyond.

By Michael Gibney • June 13, 2022

Making moves: Civica, Astellas, Inozyme and more announce key new hires

The latest hiring moves from Civica, Astella, Inozyme and the Flagship Pioneering-founded Tessera Therapeutics. 

By Karissa Waddick • June 13, 2022

A combo of precision meds and diagnostics could disrupt mental healthcare

HMNC Brain Health, a clinical-stage company, is leveraging cutting-edge tech to offer a new approach to mental health challenges.

By Kelly Bilodeau • June 8, 2022

First 90 Days: Janssen Immunology’s David Jimenez

The long-time company man discusses the mega-drugmaker’s plans for growth and why, if you meet with him, you should plan on sipping coffee.

By Taren Grom • June 6, 2022

Flagship's creative approach to finding the next big idea in biopharma

Avak Kahvejian, partner at Flagship Pioneering, a company that conceives, creates and launches bioplatform companies like Moderna, discusses its latest venture, ProFound Therapeutics.

By Alexandra Pecci • June 1, 2022

Cell and gene therapy advances coming fast and furious

A peek into R&D at the Mass General Brigham network reveals up-and-coming treatments pushing the boundaries of what’s possible in medicine.

By Kelly Bilodeau • June 1, 2022

Woman of the Week: OcuTerra Therapeutics' Kerrie Brady

The serial entrepreneur and now head of OcuTerra explains why taking risks in pharma pays off.

By Taren Grom • June 1, 2022

Making moves: Inovio, Veru, MindMed and more announce key new hires

The latest career moves in the biopharma industry from Veru, MindMed, Horizon Therapeutics and Inovio. 

By Karissa Waddick • May 25, 2022

First 90 Days: Syneos Health’s Michelle Keefe

The newly minted CEO is leaning on her 30 years of experience leading high-performance teams to make her mark at Syneos.

By Taren Grom • May 23, 2022

The UK-based company that's striving to overcome the limitations of T cell receptor innovation

Etcembly’s CEO, Michelle Teng, shares why a platform approach to T cell receptors can advance and democratize innovation.

By Kim Ribbink • May 23, 2022

Tracking trends in healthcare, from tech to patient care

High-performing leaders honored by the Healthcare Businesswomen’s Association share their views on the future of the industry.

By Taren Grom • May 20, 2022